Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.785 EUR | 0.00% |
|
+3.97% | -7.65% |
25/06 | 3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024 | CI |
25/06 | 3Sbio Inc. Announces Board Changes | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Its low valuation, with P/E ratio at 8.65 and 7.87 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.65% | 1.99B | - | ||
+7.46% | 100B | A- | ||
+8.42% | 42.34B | A- | ||
-13.04% | 32.76B | B- | ||
+80.74% | 29.46B | A | ||
-10.92% | 16.31B | C | ||
+1.93% | 14.39B | B- | ||
-6.77% | 12.23B | D+ | ||
+177.16% | 10.47B | D | ||
-1.35% | 8.97B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1530 Stock
- 83B Stock
- Ratings 3SBio Inc.